Form CT-648

Comprehensive Analysis of New York Form CT-648 and the Life Sciences Research and Development Tax Credit

Form CT-648 is the specific New York State tax form used by corporations to claim the Life Sciences Research and Development Tax Credit against their franchise tax liability. It serves as a mechanism for newly established life science companies to receive a fully refundable credit of up to 20% of their qualified research expenditures, provided they are certified by Empire State Development.

The emergence of the life sciences sector as a critical pillar of the New York State economy represents a strategic shift in regional industrial policy, aimed at transforming the state into a global hub for biotechnology, pharmaceuticals, and medical innovation. Form CT-648 is the technical instrument through which this policy is realized for corporate taxpayers under Article 9-A of the Tax Law. Unlike many standard business incentives that offer mere offsets against tax liability, the Life Sciences Research and Development Tax Credit is distinguished by its full refundability, a feature designed to provide vital liquidity to pre-revenue startups that have significant research costs but no current tax burden. This analysis provides an exhaustive exploration of the credit’s legal framework, the administrative interplay between various state agencies, the rigorous definitions of eligible entities and expenditures, and the practical mechanics of filing Form CT-648.

The Regulatory and Legislative Context of the Credit

The Life Sciences Research and Development Tax Credit Program was formally established as part of a broader “Life Science Initiative,” a statewide effort initially backed by a $620 million commitment to support the commercialization of life science innovations. This initiative recognized that the high cost of laboratory space, specialized talent, and lengthy regulatory pathways for medical products required a more aggressive incentive structure than was previously available under the general Research and Development tax credit or the Excelsior Jobs Program.

Legal Authority under the Tax Law

The primary legal authority for the credit is found in New York Tax Law Section 43, which outlines the allowance of the credit, and Section 210-B(52), which integrates the credit into the corporate franchise tax regime. For companies subject to the personal income tax—such as sole proprietors or partners in a partnership—the credit is claimed using Form IT-648 under Article 22, while corporate entities use Form CT-648 under Article 9-A. This distinction is critical for tax compliance, as the rules for calculating and reporting the credit must be consistently applied across different tax bases while ensuring that no “double dipping” occurs between different state incentive programs.

The program is fundamentally a collaborative effort between the New York State Department of Taxation and Finance and the Department of Economic Development, more commonly known as Empire State Development (ESD). While the Tax Department manages the processing of Form CT-648 and the issuance of refunds, ESD acts as the certifying authority that determines which businesses qualify as “life sciences companies” and which expenses are “qualified”. This dual-agency oversight ensures that the credit is targeted specifically toward the industries and activities intended by the legislature.

Administrative Guidance and TSB-Ms

The Department of Taxation and Finance periodically issues Technical Services Bureau Memoranda (TSB-Ms) and other guidance to clarify legislative changes. For instance, TSB-M-17(4)C and other related notices have historically clarified the interaction between new credits and existing surcharges, such as the Metropolitan Transportation Business Tax (MTA surcharge), against which the Life Sciences credit cannot be applied. Furthermore, the instructions for Form CT-1 highlight that the Life Sciences Research and Development Tax Credit was created as part of a suite of new incentives, including the Farm Donations to Food Pantries Credit and the Empire State Apprenticeship Tax Credit, reflecting a period of high legislative activity in targeted economic development.

Defining the Qualified Life Sciences Company

The threshold for using Form CT-648 is the successful certification of the taxpayer as a “qualified life sciences company.” This is not a status that a company can self-proclaim on its tax return; rather, it requires a rigorous application process to ESD and the subsequent issuance of a Certificate of Tax Credit.

Scope of Eligible Life Science Fields

The program uses a broad but technically specific definition of life sciences to capture a wide range of innovative activities. According to ESD regulations and statutory definitions, the term encompasses any business entity that devotes the majority of its efforts to research, development, technology transfer, and commercialization in the following fields:

Life Science Discipline	Description of Qualifying Activities
Agricultural Biotechnology	Improvements in crop yield, resistance to pests, and bio-based fuel research.
Biogenerics	Development of biosimilar medicines and follow-on biologics.
Bioinformatics	Utilization of computer science and statistics for biological data analysis.
Biomedical Engineering	Designing medical equipment, diagnostic tools, and therapeutic devices.
Biopharmaceuticals	Research into drugs derived from biological sources (e.g., vaccines, proteins).
Chemical Synthesis	Development of new chemical compounds for medical or industrial use.
Genomics	Analysis of the structure, function, and evolution of genomes.
Medical Devices	Innovative hardware for surgical, diagnostic, or patient-monitoring applications.
Medical Nanotechnology	Precision medical applications at the molecular or atomic scale.
Proteomics	Large-scale study of proteins and their role in disease.

The intent of this wide scope is to support the entire value chain of the medical and biological research sectors, from basic genomic research to the manufacturing of advanced medical devices. However, the guidance explicitly excludes certain entities, such as medical or veterinary laboratory testing facilities that perform routine diagnostic services rather than novel research and development.

The Essential “New Business” Prerequisite

A foundational requirement for the Life Sciences Research and Development Tax Credit is that the applicant must be a “new business.” This requirement ensures that the state’s $10 million annual credit pool is directed toward emerging startups rather than being absorbed by established companies that are simply rebranding existing activities.

To satisfy the “new business” test under New York State Tax Law, a company must meet the following criteria:

• Ownership Limitation: If the company is a C-corporation, no more than 50% of its ownership or control can be held by another company that is already a taxpayer in New York State.
• Operational Independence: The company cannot be “substantially similar” in ownership and operation to another business that is, or previously was, a taxpayer in the state. This prevents existing firms from spinning off divisions into new entities purely for tax advantages.
• Temporal Limit: The business entity, or its individual owners, must not have operated the same new business in New York for more than five years prior to the application for the credit.
• Relocation Eligibility: A business that moves into New York from another state can qualify as a new business, provided it passes the other tests for ownership and operational similarity.

Qualified Research and Development Expenditures (QREs)

The credit amount reported on Form CT-648 is derived from a company’s Qualified Research Expenditures (QREs) incurred within New York State. While the program’s definitions are rooted in Federal tax concepts, specifically Internal Revenue Code (IRC) Section 41(b), New York has introduced several critical modifications that taxpayers must navigate carefully.

Inclusions and Exclusions in QREs

The primary divergence between the Federal R&D credit and the New York Life Sciences credit is the geographic and categorical limitation of expenses. For the purpose of Form CT-648, only expenses incurred within the physical borders of New York State are eligible.

Expense Category	New York Life Sciences Credit Treatment	Rationale for Treatment
Wages	Included if work is performed in NY.	Rewards in-state job creation and talent retention.
Supplies	Included if used in NY-based research.	Incentivizes the build-out of NY laboratory facilities.
Computer Leases/Rentals	Included if computers are used for NY research.	Supports cloud and high-performance computing needs.
Contract Research	Excluded	Encourages in-house innovation over outsourcing.
Out-of-State Costs	Excluded	Focuses benefits strictly on the New York economy.

The exclusion of contract research expenses is particularly significant for biotechnology startups, which often rely heavily on Contract Research Organizations (CROs) for clinical trials. For Form CT-648, these payments are non-qualified. The credit is specifically designed to incentivize companies to build their own internal research capacity and laboratory infrastructure within New York.

Applying the Federal Four-Part Test

Despite the state-specific exclusions, the underlying activities must still satisfy the Federal “Four-Part Test” to qualify as research and development. This ensures that the state is subsidizing genuine scientific experimentation rather than routine business operations.

The four components of the test are as follows:

1. Permitted Purpose: The research must be aimed at creating a new or improved business component, such as a product, process, or software platform.
2. Technological in Nature: The activity must rely on principles of the “hard” sciences, such as biology, chemistry, or physics.
3. Elimination of Uncertainty: The taxpayer must intend to discover information that would eliminate uncertainty concerning the capability, method, or design of the business component.
4. Process of Experimentation: The research must involve a systematic evaluation of alternatives, such as through modeling, simulation, or trial-and-error testing.

Calculation Methodology and Tiered Rates

The Life Sciences Research and Development Tax Credit utilizes a tiered percentage system that rewards smaller, early-stage companies with a higher rate of return on their research spending. This tiered structure is a core component of the calculation on Schedule A of Form CT-648.

Employment Tiers and Credit Rates

The applicable credit rate depends on the number of people the company employs during the tax year. This headcount is determined by taking the average number of full-time employees (excluding general executive officers) on March 31, June 30, September 30, and December 31.

Employment Threshold	Applicable Credit Rate
Fewer than 10 Employees	20% of NYS QREs
10 or More Employees	15% of NYS QREs

This mathematical structure means that a startup with a small, lean research team can recover one-fifth of its qualifying costs annually in the form of a cash refund. If the company’s headcount increases above ten during a subsequent tax year, the rate automatically adjusts to 15% for that period.

Program Caps and Duration Limits

The credit is subject to strict limitations at the individual and statewide levels to manage the fiscal impact on the state budget.

• Annual Individual Cap: A single taxpayer (or combined group) cannot claim more than $500,000 in credits in any single tax year.
• Lifetime Duration: A qualified company can claim the credit for a maximum of three consecutive years.
• Lifetime Value Cap: Given the annual cap and the three-year limit, the maximum total benefit any single company can receive from the program is $1.5 million.
• Statewide Annual Pool: The total amount of credits allocated across all participants is capped at $10 million per year. These credits are awarded on a “first-come, first-served” basis based on the application date to ESD.

The Form CT-648 Breakdown: Line-by-Line Application

Filling out Form CT-648 requires the taxpayer to transfer data from their ESD Certificate of Tax Credit and reconcile it with their general corporate franchise tax filing.

Schedule A: Computation of Credit

In this section, the taxpayer enters the total amount of the credit exactly as it appears on the ESD certificate. If a taxpayer has received more than one certificate (for example, for different projects or from a partnership interest), they must file a separate Form CT-648 for each certificate. The entry on Line 1 is strictly capped at $500,000; any amount allocated by ESD above this threshold must be truncated at the individual entity level.

Schedule B: Combined Filer Limitation

Schedule B is mandatory for corporations filing as part of a combined group on Form CT-3-A. This schedule is designed to ensure that the $500,000 annual limit is maintained for the entire group, even if multiple members are certified as life sciences companies. The form requires the reporting of all other tax credits applied before the Life Sciences credit to ensure the proper ordering of incentives.

Schedule C: Partnership Information

If the taxpayer is a corporate partner in a partnership that has been certified for the credit, Schedule C is used to report the pass-through share of that credit. The taxpayer must provide the partnership’s name, Employer Identification Number (EIN), the specific ESD certificate number, and the dollar amount allocated to the corporate partner. This ensures a clear audit trail from the partnership entity that conducted the research to the corporate partner claiming the benefit.

Schedule D: Computation of Credit Used or Refunded

This schedule determines the actual cash benefit the taxpayer will receive.

• Line 6: The taxpayer enters their total franchise tax liability from Form CT-3 or CT-3-A.
• Line 7: Other credits claimed prior to the Life Sciences credit are subtracted. New York has a specific “order of credits” that must be followed.
• Line 11: The credit is used to reduce the tax liability, but not below the “fixed dollar minimum tax”.
• Lines 12-13: Any unused portion of the credit—which for many startups is the entire amount—is then claimed as a refund or applied as an overpayment to the following year’s tax.

The Administrative Journey: From CFA to Refund

The process of securing the benefit of Form CT-648 is a multi-step administrative marathon that begins long before the tax return is filed.

Step 1: The Consolidated Funding Application (CFA)

The initial step for any company seeking the Life Sciences credit is the submission of a Consolidated Funding Application (CFA) to the appropriate ESD regional office. This application requires the company to provide:

• Evidence of its “new business” status.
• Detailed descriptions of its research projects.
• Projections of its New York State employment and R&D spending.
• Documentation confirming it is operating in a qualified life sciences field.

Step 2: Certification and Allocation

ESD evaluates the application based on the program’s eligibility standards and the availability of funds within the $10 million annual cap. If the application is approved, ESD admits the company to the program and issues a Certificate of Tax Credit. This certificate is the essential prerequisite for filing Form CT-648 and must be attached to the corporate tax return.

Step 3: Annual Compliance and Re-application

Because the credit is only allowed for three consecutive years, and the employment tiers can change, the company must apply for a new certificate for each of the three tax years. This involves submitting updated performance reports to ESD to verify that the company continues to meet all eligibility criteria and that the research was actually conducted as planned.

Step 4: Tax Filing and Refund Processing

Once the taxpayer possesses the certificate, they file Form CT-648 with their New York S-Corporation (CT-3-S) or C-Corporation (CT-3) return. If the return is in “processible form”—meaning it is properly signed and includes all required attachments—the Department of Taxation and Finance will process the refund. The department does not pay interest on these refunds, as they are considered tax overpayments rather than standard commercial returns.

Comprehensive Business Scenario: Albany BioGenetics Corp

To illustrate the interplay of these rules, consider the following example of a hypothetical entity, “Albany BioGenetics Corp,” a new firm founded in 2022 to develop bioinformatics software for cancer diagnostics.

Scenario Parameters

• Entity Structure: C-Corporation, subject to tax under Article 9-A.
• Employment: The company averaged 7 full-time employees in 2023.
• Research Activities: Developing novel algorithms for genomic sequencing.
• Tax Liability: Pre-revenue, with a fixed dollar minimum tax of $25.
• Expenditures in New York State:

• Wages for research scientists: $1,500,000
• Laboratory supplies: $300,000
• Cloud-based computer rentals for data processing: $200,000
• Outsourced clinical validation to a New Jersey-based lab: $500,000

Expenditure Analysis and Calculation

The company must first filter its expenses based on New York’s specific QRE rules.

• The $500,000 paid to the New Jersey lab is excluded because it was incurred out-of-state and is considered contract research, which is ineligible for Form CT-648.
• The remaining New York-based expenditures ($1.5M wages + $300k supplies + $200k computer rentals) total $2,000,000 in qualifying NYS QREs.

Because Albany BioGenetics has fewer than 10 employees, it qualifies for the 20% credit rate.

• Calculation: $2,000,000 \times 0.20 = $400,000.

Filing Mechanics

The company applies to ESD and receives a Certificate of Tax Credit for $400,000. When filing Form CT-648:

1. Schedule A, Line 1: The company enters $400,000.
2. Schedule D, Line 6: Total tax liability is $25.
3. Schedule D, Line 11: The credit is used to pay the $25 tax.
4. Schedule D, Line 13: The remaining $399,975 is requested as a fully refundable cash payment.

This cash infusion allows Albany BioGenetics to fund its next round of research without having to dilute equity or wait until it reaches profitability to realize a tax benefit.

Comparison with the Excelsior Jobs Program R&D Credit

Many life science companies may be eligible for multiple programs, most notably the Research and Development Tax Credit housed within the Excelsior Jobs Program. New York law strictly prohibits taxpayers from claiming the Life Sciences R&D credit and the Excelsior R&D credit for the same expenses.

The choice between these programs is a strategic one, based on the company’s long-term goals and immediate cash needs.

Feature	Life Sciences R&D Credit (CT-648)	Excelsior Jobs R&D Credit
Eligibility Focus	New life science startups.	Strategic industries (IT, Mfg, Bio).
Job Creation Requirement	No minimum new jobs required.	5 net new jobs for R&D firms.
Duration of Benefit	3 consecutive years.	10 years.
Credit Rate	15% or 20% of NYS QREs.	50% of Federal Credit (capped at 6-8% of QREs).
Annual Limit	$500,000 per year.	Varies by individual benefit schedule.
Refundability	Fully Refundable.	Fully Refundable.

The Life Sciences R&D credit is often superior for very early-stage startups that have massive research spending but are not yet ready to commit to the rigorous job growth targets required to maintain Excelsior eligibility. However, for a company planning to scale significantly over a decade, the 10-year window of the Excelsior program may ultimately provide a larger cumulative benefit.

Statistical Performance and Economic Outlook

The Life Science Initiative has shown measurable success in fostering an innovation ecosystem. Since its legislative authorization in 2017, the program has been a cornerstone of New York’s industrial policy.

According to ESD’s 2023 Annual Report, the broader initiative has committed over $221 million for strategic programs through October 2023. Specifically regarding tax credits, between April 2022 and October 2023, approximately $3.66 million in Life Science R&D tax credits were issued against $34.68 million in qualified research expenses.

Economic Indicator (2017-2022)	Percentage Growth / Number
Life Science Companies in NY	27.1% Growth
Life Science Jobs in NY	18.5% Growth
New Lab Space in NYC	Over 3.1 Million Square Feet
New Companies Formed/Retained	32
New Patents Filed/Granted	181

The job growth rate in the life sciences sector (18.5%) has significantly outpaced the overall private sector growth rate in New York (by 18.5%) and the national private sector growth rate (by 13.3%) during the same period. This data suggests that the combination of strategic grants and refundable tax credits like CT-648 is effectively driving specialized employment in the state.

Compliance, Audit Readiness, and Documentation

Given the high value and refundable nature of the credit, the New York State Tax Department is highly likely to audit claims made on Form CT-648. To survive such scrutiny, companies must maintain an impeccable audit trail that demonstrates both their eligibility and the qualifying nature of their research activities.

The Importance of Contemporaneous Records

Documentation must be “contemporaneous,” meaning it must be created as the research occurs, not reconstructed years later during an audit. Taxpayers should preserve the following types of records for at least three to four years after filing:

• Payroll Substantiality: Timesheets or project-tracking software data that identifies the specific hours scientists and lab technicians spent on qualified research projects versus administrative duties.
• Project Records: Lab notebooks, experimental protocols, prototype designs, and test results that prove a “process of experimentation” was occurring.
• General Ledgers: Financial records that clearly code and segregate in-state R&D expenses (wages, supplies, computer costs) from ineligible costs like out-of-state CRO payments or marketing expenses.
• Certification Documentation: All copies of the ESD CFA application, the resulting Certificate of Tax Credit, and any performance reports submitted to ESD to maintain eligibility.

Common Audit Risks

Audit challenges often arise when a company fails to properly distinguish between research and routine activities. For example, clinical validation that is purely repetitive or “black box” software development that does not face significant technological uncertainty may be disqualified upon review. Furthermore, because the $500,000 cap is applied at the combined group level, companies with complex corporate structures must be extremely careful to consolidate their claims correctly on Schedule B of Form CT-648 to avoid over-claiming.

Strategic Coordination with Other New York Incentives

Beyond the CT-648 credit, New York offers a “stackable” environment where life science companies can leverage multiple incentives simultaneously, provided the same expenses are not used for more than one credit.

START-UP NY

The START-UP NY program allows eligible businesses that locate on or near certain academic campuses to operate tax-free for up to ten years. For a life science company, this can include exemptions from corporate franchise taxes, sales taxes, and personal income taxes for its employees. A startup could potentially claim the Life Sciences R&D credit for its research expenditures while benefiting from the broader tax-free status of START-UP NY, provided its research budget is managed through separate accounting to avoid “double-benefit” conflicts.

NYFIRST and Entrepreneur Development Grants

The state also provides direct funding through programs like the New York Fund for Innovation in Research and Scientific Talent (NYFIRST), which has awarded over 12 grants of up to $1 million each to medical schools to recruit top-tier scientific talent. Additionally, the Entrepreneur Development Grant Program has awarded nearly $3 million to business schools to help life science researchers transition their work from the lab to the commercial market.

Final Thoughts: Maximizing the Value of Form CT-648

Form CT-648 represents a significant opportunity for New York’s burgeoning life sciences sector to capitalize on its innovation before reaching profitability. By providing a 15% to 20% refundable credit on the most critical inputs of research—wages, supplies, and computing power—the state has created a powerful catalyst for economic growth. However, the program’s success depends on rigorous compliance. From the initial CFA application to the line-by-line reconciliation on Form CT-648, companies must be meticulous in their documentation and strategic in their timing to secure a portion of the limited $10 million annual pool.

For the corporate executive or the startup founder, the Life Sciences Research and Development Tax Credit is more than just a line item on a tax return; it is a strategic asset that can fund new prototypes, hire additional researchers, and accelerate the delivery of life-saving medical innovations. As the competition for biotechnology investment intensifies globally, New York’s commitment to this refundable credit ensures that the state remains a premier destination for the next generation of life science leaders. Success in this environment requires a proactive partnership between the company’s scientific leaders, who drive the experimentation, and its tax professionals, who must navigate the technical complexities of Form CT-648 to ensure the full realization of the state’s innovative incentives.